- Dr Ball on Data From from the IMerge Trial in Low🔍
- OncLive.com on X🔍
- Making Headway in MDS🔍
- Myeloproliferative Neoplasms🔍
- Imetelstat in Lower|Risk MDS🔍
- Geron Announces New Data to be Presented at Upcoming ASH ...🔍
- Geron Announces Data Presentations from IMerge Phase 3 ...🔍
- Management of Patients with Lower|Risk Myelodysplastic ...🔍
Dr Ball on Data From from the IMerge Trial in Low
Dr Ball on Data From from the IMerge Trial in Low - OncLive
Previously reported data from the COMBI I trial established the safety and efficacy of Peg-IFN-α2a plus ruxolitinib in patients with PV and ...
OncLive.com on X: ".@drsomedeb, of @VUMC_Cancer, discusses ...
Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS. Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial ...
Making Headway in MDS: Two Novel Agents for Advanced Lower ...
... Dr. Ball said. Imetelstat was approved based on results from the phase III IMerge study, which randomly assigned 178 patients with low-risk ...
Myeloproliferative Neoplasms | Clinical Oncology News | Page 2
Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.
Imetelstat in Lower-Risk MDS: IMerge Trial Overview and Efficacy ...
Dr. Michael Savona: And now, we're going to talk a little bit about this new drug called imetelstat telomerase inhibitor.
Geron Announces New Data to be Presented at Upcoming ASH ...
New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with ...
Geron Announces Data Presentations from IMerge Phase 3 ...
Based on results from the IMerge Phase 3 clinical trial, Geron submitted a New Drug Application for imetelstat in lower risk MDS that was ...
Management of Patients with Lower-Risk Myelodysplastic ...
Deferasirox was approved for the treatment of chronic iron overload in patients with transfusion-dependent anemias based on data from clinical trials in ...
▷ Dr. ... Real-World Data. ASH, American Society of ... So, the phase. 3 IMerge trial randomized patients that were lower-risk. MDS.
1-Year Follow-up of Efficacy Data and Safety Outcomes of Imetelstat ...
But this did not seem to replicate in the MDS studies that use the 7.5 lower gram in the IMerge study. Dr. Michael Savona: That's completely ...
Myelodysplastic syndromes: 2023 update on diagnosis, risk ...
Data from a phase II trial of clofarabine and low dose ara-C in patients with relapsed refractory MDS indicated that lower doses of this ...
Amer Zeidan, MBBS - Yale School of Medicine
Dr. Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the ...
The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
Risk-Adapted, Individualized Treatment Strategies of ...
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are two blood cancers with variable symptoms of low blood counts (fatigue, ...
66th ASH Annual Meeting: 637. Myelodysplastic Syndromes ...
... Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial. Katharina S. S. Götze, MD1,2,3, Anna Hecht, MD4*, Anne Sophie ...
Rami Komrokji, MD - Moffitt Cancer Center
Dr Komrokji is expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in ...
Mikkael Sekeres Publications | Ohio Innovation Exchange
... IMerge Phase 3 Trial of RBC-Transfusion Dependent ... Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior ...
The recent approval of imetelstat in LR-MDS based on ... - VJHemOnc
In the IMerge trial (NCT02598661), which led to its approval, imetelstat administration resulted in a 40% transfusion independence rate and an ...
María DÍEZ-CAMPELO | PhD | Doctor of Medicine | Research profile
In the absence of evidence from randomized trials, real-world observational data become beneficial to study the effect of... View.
Amer Zeidan, MBBS < SEICHE Center for Health and Justice
Dr. Zeidan completed a hematology/oncology ... data and safety monitoring committees of multiple clinical trials. ... Ball B, Stahl M. Intensive ...